PT2804875T - Ferramentas e métodos para expressão de proteínas de membrana - Google Patents

Ferramentas e métodos para expressão de proteínas de membrana

Info

Publication number
PT2804875T
PT2804875T PT137007514T PT13700751T PT2804875T PT 2804875 T PT2804875 T PT 2804875T PT 137007514 T PT137007514 T PT 137007514T PT 13700751 T PT13700751 T PT 13700751T PT 2804875 T PT2804875 T PT 2804875T
Authority
PT
Portugal
Prior art keywords
tools
expression
methods
membrane proteins
proteins
Prior art date
Application number
PT137007514T
Other languages
English (en)
Portuguese (pt)
Inventor
Steyaert Jan
Callewaert Nico
Laeremans Toon
Pardon Els
Vandewalle Kristof
Claes Katrien
Original Assignee
Univ Brussel Vrije
Vib Vzw
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brussel Vrije, Vib Vzw, Univ Gent filed Critical Univ Brussel Vrije
Publication of PT2804875T publication Critical patent/PT2804875T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT137007514T 2012-01-19 2013-01-21 Ferramentas e métodos para expressão de proteínas de membrana PT2804875T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588523P 2012-01-19 2012-01-19
EP12151814.6A EP2617732A1 (fr) 2012-01-19 2012-01-19 Outils et procédés pour l'expression de protéines de membrane

Publications (1)

Publication Number Publication Date
PT2804875T true PT2804875T (pt) 2017-07-13

Family

ID=45524342

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137007514T PT2804875T (pt) 2012-01-19 2013-01-21 Ferramentas e métodos para expressão de proteínas de membrana

Country Status (7)

Country Link
US (3) US9890217B2 (fr)
EP (2) EP2617732A1 (fr)
AU (1) AU2013211001B2 (fr)
CA (1) CA2861393C (fr)
DK (1) DK2804875T3 (fr)
PT (1) PT2804875T (fr)
WO (1) WO2013107905A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785135B2 (en) 2007-03-22 2014-07-22 Heptares Therapeutics Limited Mutant G-protein coupled receptors and methods for selecting them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
WO2013021206A2 (fr) 2011-08-10 2013-02-14 Heptares Therapeutics Limited Protéines stables
EP2617732A1 (fr) 2012-01-19 2013-07-24 Vib Vzw Outils et procédés pour l'expression de protéines de membrane
US10458993B2 (en) * 2012-06-01 2019-10-29 Heptares Therapeutics Limited Assay for assessing conformational stability of membrane protein
DK3320105T3 (da) 2015-07-09 2021-06-07 Vib Vzw Celler, der producerer glycoproteiner med ændrede o- og o-glycosyleringsmønstre, samt tilhørende fremgangsmåder og anvendelse

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2131518T3 (es) 1991-12-23 1999-08-01 Dsm Nv Sistema de expresion eucariota.
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
WO1999037681A2 (fr) 1998-01-26 1999-07-29 Unilever Plc Procede servant a preparer des fragments d'anticorps
US6730499B1 (en) 1998-07-03 2004-05-04 Research Corporation Technologies, Inc. Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2412701A1 (fr) 2000-06-28 2002-01-03 Glycofi, Inc. Procede de production de glycoproteines modifiees
DE10062302A1 (de) 2000-12-14 2002-07-11 Aventis Res & Tech Gmbh & Co Sekretionssignalpeptide, deren DNA-Sequenzen, damit herstellbare Expressionsvektoren für eukaryotische Zellen und deren Verwendung zur biotechnologischen Herstellung von Proteinen
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
EP1433793A4 (fr) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ES2356307T3 (es) 2002-04-19 2011-04-06 Zymogenetics, L.L.C. Procedimientos para detectar o modular la interacción de un receptor de citocina con su ligando.
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
EP1639095A2 (fr) * 2003-06-11 2006-03-29 Biogen Idec MA Inc. Procede d'accroissement de la production en culture de proteines
US20100160217A1 (en) * 2005-05-04 2010-06-24 University Of Utah Research Foundation Acetylycholine gated ion channel chaperons and methods of using the same
US8815580B2 (en) 2008-08-08 2014-08-26 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and method and use thereof
AU2009326075B2 (en) 2008-12-08 2014-06-05 Complix Nv Single-chain antiparallel coiled coil proteins
WO2010135678A1 (fr) 2009-05-22 2010-11-25 Research Corporation Technologies, Inc. Acides nucléiques de pichia pastoris et utilisation de ceux-ci pour la production recombinante de protéines
CA2802775C (fr) 2010-06-17 2019-09-24 Vib Vzw Expression des proteines augmentee par le developpement accru de leur membrane
EP2617732A1 (fr) 2012-01-19 2013-07-24 Vib Vzw Outils et procédés pour l'expression de protéines de membrane

Also Published As

Publication number Publication date
US11479791B2 (en) 2022-10-25
US9890217B2 (en) 2018-02-13
EP2804875A1 (fr) 2014-11-26
EP2617732A1 (fr) 2013-07-24
AU2013211001B2 (en) 2017-03-09
US20230071321A1 (en) 2023-03-09
DK2804875T3 (en) 2017-08-14
US20140357521A1 (en) 2014-12-04
WO2013107905A1 (fr) 2013-07-25
US20180237530A1 (en) 2018-08-23
EP2804875B1 (fr) 2017-04-19
CA2861393A1 (fr) 2013-07-25
AU2013211001A1 (en) 2014-09-04
CA2861393C (fr) 2020-02-04

Similar Documents

Publication Publication Date Title
HK1212256A1 (en) Anti-mcam antibodies and associated methods of use -mcam
SG11201510747RA (en) Method for increasing expression of rna-encoded proteins
EP2852687A4 (fr) Procédés de préparation d'un échantillon
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
EP2721063A4 (fr) Polypeptides liant pcsk9 et leurs procédés d'utilisation
EP2968549A4 (fr) Procédés de culture de cellules
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
EP2877854A4 (fr) Protéines de fusion et leurs procédés associés
EP2971014A4 (fr) Méthodes de culture cellulaire
EP2971040A4 (fr) Procédés de culture cellulaire
HK1213521A1 (zh) 多肽的應用
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
ZA201400562B (en) Axmi205 variant proteins and methods for their use
GB201222833D0 (en) Detection of membrane proteins
EP2992083A4 (fr) Analyse de l'adn
HK1203161A1 (en) Peptides and methods of using same
EP2938632A4 (fr) Anticorps anti-granulysine et leurs procédés d'utilisation
HK1209432A1 (en) Anti-jagged antibodies and methods of use
HK1207659A1 (en) Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins
PT2804875T (pt) Ferramentas e métodos para expressão de proteínas de membrana
IL219244A0 (en) Splitting of user-lists
EP2808388A4 (fr) Vecteur d'expression et procédé de production de protéines
EP2922871A4 (fr) Procédés et compositions pour protéines facteur ix
EP2797611A4 (fr) Procédé pour l'isolement, l'utilisation et l'analyse de la ferritine
EP3560952C0 (fr) Variante de protéine bpifb4